Infectious Diseases Self-Assessment Program (IDSAP) 2025 (L259081)
ACPE Numbers: Various – see listing below
Release Date: May 15, 2025
Expiration Dates: May 15, 2026
Activity Type: Application-based
CE Credits: 23 contact hours (BPS and ACPE)
Activity Fee: $88 (ASHP member); $132 (non-member)
Activity Overview
This course is intended for board-certified pharmacists in need of recertification credit and is designed based on the content outline developed by Board of Pharmacy Specialties (BPS). The course consists of 9 learning modules (see table below) and provides up to 23 contact hours of continuing pharmacy education and/or recertification credit.
Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.
These activities are part of the ACCP and ASHP professional development program for BCIDP recertification approved by the BPS.
Accreditation
![]() |
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation. |
![]() |
The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education. |
Target Audience
The target audience for BCIDP 2025 is pharmacotherapy specialists and advanced-level clinical pharmacists whose responsibilities may include providing care for individuals with or at risk for infectious diseases.
Recertification Credit
Board-certified pharmacists are eligible to receive up to 23 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.
ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.
ACCP and ASHP are approved by BPS as a provider for the recertification of BCIDP .
Learning Activity |
Passing Score |
Credit Information |
Acinetobacter baumannii |
73% |
3.0 Contact Hours BPS: BCIDP |
Pseudomonas aeruginosa |
80% |
2.5 Contact Hours BPS: BCIDP |
Enterobacterales |
80% |
2.0 Contact Hours BPS: BCIDP |
Hepatitis C and Hepatitis B Viruses |
80% |
2.0 Contact Hours BPS: BCIDP |
Community Pharmacy Point-of-Care Test and Treat Programs for Respiratory Tract Infections |
80% |
1.5 Contact Hours BPS: BCIDP |
Herpesviruses in Immunocompromised Patients |
80% |
3.0 Contact Hours BPS: BCIDP |
Application of NHSN Antimicrobial Use and Resistance Data |
73% |
2.5 Contact Hours BPS: BCIDP |
TJC/CMS Regulatory Updates |
83% |
3.0 Contact Hours BPS: BCIDP |
β-Lactam Therapeutic Drug Monitoring |
73% |
3.5 Contact Hours BPS: BCIDP |
Learning Objectives
Chapter: Acinetobacter baumannii
ACPE: 0217-9999-25-078-H01-P
- Classify the global epidemiology of Acinetobacter, highlighting its resistance patterns, regional variations in susceptibility rates, and the evolution and dissemination of clonal lineages.
- Assess the biological and ecological features of Acinetobacter, its increasing virulence, and the challenges it poses in clinical settings because of drug resistance and its role in nosocomial infections.
- Analyze the various exogenous and endogenous resistance mechanisms employed by Acinetobacter isolates and their impact on therapeutic efficacy.
- Evaluate current and emerging antimicrobial therapies for Acinetobacter infections.
Chapter: Pseudomonas aeruginosa
ACPE: 0217-9999-25-079-H01-P
- Classify the microbiology, epidemiology, pathogenesis, and mechanisms of resistance of infections caused by Pseudomonas aeruginosa.
- Distinguish differences in patient characteristics or risk factors that increase the likelihood for an infection caused by P. aeruginosa including multidrug resistant strains.
- Design a therapeutic regimen for a patient with suspected or confirmed P. aeruginosa infection.
- Justify the pharmacist’s role with antimicrobial and diagnostic stewardship in the management of patients with P. aeruginosa infections.
Chapter: Enterobacterales
ACPE: 0217-9999-25-080-H01-P
- Distinguish the changing epidemiology and taxonomic updates associated with Enterobacterales.
- Assess likely mechanisms of resistance in Enterobacterales given a susceptibility report.
- Interpret and apply updated susceptibility test interpretative criteria (ie, breakpoints) and reporting strategies on the basis of genotypic and phenotypic results.
- Evaluate the clinical relevance and spectrum of activity for recently approved and late-stage pipeline agents.
- Devise an appropriate treatment regimen for an Enterobacterales infection considering relevant phenotypes, genetic information, clinical factors, and best practice recommendations.
Chapter: Hepatitis C and Hepatitis B Viruses
ACPE: 0217-9999-25-081-H01-P
- Evaluate a patient for hepatitis B virus (HBV) infection using serology and laboratory findings.
- Distinguish among therapeutic options for various patient populations with HBV infection.
- Evaluate a patient’s risk of HBV infection and need for vaccination or revaccination.
- Evaluate a patient for hepatitis C virus (HCV) infection before, during, and after HCV therapy.
- Distinguish the use of the specific therapies in various patient populations with HCV infection.
Chapter: Community Pharmacy Point-of-Care Test and Treat Programs for Respiratory Tract Infections
ACPE: 0217-9999-25-082-H01-P
- Distinguish differences between CLIA-waived and other POCTs.
- Using clinical guidelines, evaluate patients for potential community pharmacy POCT and treatment of respiratory tract infections.
- Compose a plan for implementing a POCT and treat program in a community pharmacy.
- Apply the appropriate statistical method for the best diagnostic accuracy of respiratory pathogen CLIA-waived POCTs.
- Determine effectiveness of community pharmacy POCT and treat programs based on published studies.
- Develop a plan for addressing barriers to implementation of community pharmacy POCT and treat programs.
Chapter: Herpesviruses in Immunocompromised Patients
ACPE: 0217-9999-25-083-H01-P
- Evaluate epidemiologic and patient risk factors associated with herpesvirus infections.
- Develop prophylactic therapy plans against herpesviruses for the immunocompromised host (hematopoietic stem cell transplant and solid organ transplant).
- Design therapeutic treatment plans for patients with herpes simplex viruses, varicella zoster virus/herpes zoster, and cytomegalovirus.
- Develop a plan to detect and manage drug-resistant herpesvirus infections.
Chapter: Application of NHSN Antimicrobial Use and Resistance Data
ACPE: 0217-9999-25-084-H01-P
- Demonstrate knowledge of the National Healthcare Safety Network (NHSN) reporting requirements for antimicrobial use and resistance (AUR).
- Develop an institutional or health-system specific plan for submitting AUR data to NHSN
- Construct reports for AUR data to include the required data elements.
- Perform an analysis of AUR data using available data analysis and reporting tools available through NHSN.
- Apply NHSN data to identify potential antimicrobial stewardship targets and assess the impact of stewardship intervention.
Case Series: TJC/CMS Regulatory Updates
ACPE: 0217-9999-25-085-H01-P
- Account for the history and importance of antimicrobial stewardship.
- Distinguish updates to the CDC and CMMS antimicrobial stewardship elements and how they relate to accreditation bodies, including the Joint Commission
- Evaluate appropriate resources; relevant accreditation, legal, regulatory and safety requirements; and quality metrics as they relate to antimicrobial stewardship.
- Assess the effectiveness of antimicrobial stewardship strategies.
- Assess institutional readiness for upcoming accreditation survey.
Chapter: β-Lactam Therapeutic Drug Monitoring
ACPE: 0217-9999-25-086-H01-P
- Apply fundamental pharmacokinetic and pharmacodynamic principles of β-lactams in disease management.
- Distinguish patient populations at risk for alterations in β-lactam pharmacokinetics/pharmacodynamics that may benefit from β-lactam therapeutic drug monitoring (TDM) for dose optimization.
- Apply current evidence regarding the impact of β-lactam TDM on patient outcomes, including clinical outcomes such as mortality and microbiologic outcomes.
- Evaluate a patient’s β-lactam dosing regimen and provide recommendations for dose adjustment using appropriately obtained concentrations.
- Justify the pharmacist’s role in implementation of a successful β-lactam TDM program.
Faculty
Disclosures
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ACCP and ASHP require that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
The following persons in control of this activity’s content have relevant financial relationships:
Consultancies: Amanda Binkley (Shionogi); Ashlan Kunz Coyne (Abbvie); Lindsay Donohue (Fingerpaint Marketing); Brandon Hawkins (ASHP, APhA, Belmont University); Esther Fasanmi (Merck); Julie Akers (AstraZeneca, Genentech); Julie Akers (AstraZeneca, Genentech); Hunter Rondeau (Cosmas Health); Nathaniel J. Rhodes (Third Pole Therapeutics, Apothecademy, LLC, NIH and CDMRP)
Grants: Ashlan Kunz Coyne Grants (PhRMA Foundation, Society of Infectious Diseases Pharmacists); Dana Bowers (Merck Sharp & Dohme Corp); Jennifer Sparks (WV DHHR); Veena Venugopalan (Merck Pharmaceuticals); Barbara A. Santevecchi (Shionogi, Inc., AbbVie, Inc.); Nathaniel J. Rhodes (NIH [two grants], FDA)
Honoraria: Natasha Pettit (SIDP, ASHP)
ACCP Staff/Series Leaders
Consultancies: Elizabeth Dodds-Ashley (HealthTrackRX);
Navaneeth Narayanan (Beckman-Coulter)
Grants: Alan Gross (AHRQ); Navaneeth
Narayanan (Merck, Shionigi)
Royalties: Elizabeth Dodds-Ashley (UpToDate)
Honoraria: Alan Gross (APhA; PROCE); Navaneeth NarayaAstellas, Beckman-Coulter, Paratek, T2 Biosystems)
Nothing to disclose: Ed Alderman, Peter Burns, Joanna
Gillette, Brent Paloutzian, Kimma Sheldon-Old, Keri Sims
Methods and CE Requirements
Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:
- Complete the attestation statement
- Review all content
- Complete and pass the assessments
- Complete the evaluations
Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.
Development
ACCP and ASHP collaborate on infectious diseases pharmacy activities.